Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Largest Part D Plans Covered More Of Top 300 Drugs Than VA: RAND

Executive Summary

A recent analysis by the RAND Corp. of Medicare Part D formularies revealed that the largest plans in the Medicare Part D prescription drug plan covered more of the top 300 most common prescription drugs for the elderly than the Department of Veterans Affairs formulary

You may also be interested in...



CMS Aims To Reduce 2010 Part D Churn With New Benchmark Formula

CMS has found a way to reduce the number of drug plan reassignments that would be needed for low-income Medicare Part D beneficiaries in 2010 by adjusting its calculation of the low-income premium benchmark

Getting To $80 Bil.: PhRMA Expects Mix Of Rebates And Fees In Finance Bill

The Pharmaceutical Research and Manufacturers of America is expecting to make good on its pledge to contribute $80 billion to health care reform through a combination of drug rebates and fees, in addition to savings from follow-on biologics and the previously announced 50 percent discount on drugs used in the Medicare Part D donut hole

One-Quarter Of Part D Drugs Are Rebated To Plans, Rep. Waxman Reports

Twenty-seven percent of the various drug products used by Medicare Part D enrollees are subject to manufacturer rebates that reduce their price, according to a survey of the leading 12 Part D insurance providers

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel